Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 5/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 5/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 5/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 5/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 5/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167788 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1557957 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5059534 | 0.87 | GRIN2D (0.77) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8828056 | 0.84 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5059538 | 0.82 | GRIN2D (0.69) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9749886 | 0.82 | GRIN2D (0.69) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15959451 | 0.81 | MAPT (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1999794 | 0.81 | MAPT (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28519158 | 0.81 | GRIN2D (0.68) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9676414 | 0.81 | GRIN2D (0.68) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4475953-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN, Fikret (TR) | 2024-12-18 | — | — | EP | claimed |
| WO-2023154014-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN FIKRET (TR) | 2023-08-17 | — | — | WO | claimed |
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-20250161238-A1 | NMDAR Antagonists Prevent Ageing and Aging-Associated Conditions and Diseases Through Increasing 20S Proteasome Activity | SAHIN FIKRET (TR) | 2025-05-22 | — | — | US | disclosed |
| US-20250002947-A1 | RECOMBINANT MANUFACTURE OF C-20 TERPENOID ALCOHOLS | ISOBIONICS B.V. (NL) | 2025-01-02 | — | — | US | disclosed |
| EP-4367255-A1 | RECOMBINANT MANUFACTURE OF C-20 TERPENOID ALCOHOLS | Isobionics B.V. (NL) | 2024-05-15 | — | — | EP | disclosed |
| US-20240124899-A1 | METHODS FOR PRODUCTION OF NOVEL DITERPENE SCAFFOLDS | UNIV MICHIGAN STATE (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240052374-A1 | PRODUCTION OF DITERPENE ALKALOIDS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2024-02-15 | — | — | US | disclosed |
| US-11827915-B2 | Method for production of novel diterpene scaffolds | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023154014-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN FIKRET (TR) | 2023-08-17 | — | — | WO | disclosed |
| US-20230159961-A1 | BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-05-25 | — | — | US | disclosed |
| WO-2023280677-A1 | RECOMBINANT MANUFACTURE OF C-20 TERPENOID ALCOHOLS | ISOBIONICS B.V. (NL) | 2023-01-12 | — | — | WO | disclosed |
| US-20220372526-A1 | METHOD FOR PRODUCTION OF NOVEL DITERPENE SCAFFOLDS | UNITED STATES DEPARTMENT OF ENERGY | 2022-11-24 | — | — | US | disclosed |
| EP-4054542-A1 | BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS | Board Of Trustees Of Michigan State University (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-3801571-A1 | DIAGNOSIS AND TREATMENT OF IMMUNOTHERAPY-INDUCED NEUROTOXICITY | Memorial Sloan Kettering Cancer Center (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159961-A1 | BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS | GGPS1, DHPS, FDPS | GRIN2D 3837/4885GRIN3B 4028/4885GRIN1 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.